Financial Implications of GLP-1 Agonists in Metabolic Treatments | Retatrutide News

GLP-1 agonists like Retatrutide are promising for metabolic disorders, but high costs limit access. Eli Lilly is a key player in developing these treatm...
Market News · October 30, 2026